2026-03-10 The key m6A methylation regulator IGF2BP1 possesses potential prognostic value in papillary thyroid carcinoma
2026-03-05 Personalized pharmacokinetic–pharmacodynamic guided therapy via an induced pluripotent stem cell–derived multi-organoid platform in NF1-mutant breast cancer
2026-03-02 Discovery of natural apigenin analogues as lysine-specific demethylase 1 inhibitors against tumoral testicular germ cells
2026-02-25 The molecular mechanisms and potential therapeutic implications of the crosstalk between DNA methylation and metabolic reprogramming in thyroid cancer
2026-02-25 Personalized signaling pathway analysis of gastrointestinal tumors for patient stratification and drug target evaluation using clinically derived core biopsies
2026-02-20 A small molecule inhibitor of ARF GTPase protein 1 limits liver and colon cancer cell growth and metastasis
2026-02-16 Transcriptional activation of PPP1R14C by KLF7 unleashes CDK1 activity to promote lung squamous cell carcinoma
2026-02-16 Homologous recombination deficiency in primary ER-positive and HER2-negative breast cancer
2026-02-13 Molecular docking and dynamics reveal novel CDK6 inhibitors for targeted glioblastoma therapy
2026-02-12 UBE2M as a bridge spanning neddylation and cell cycle regulation in colorectal adenocarcinoma
2026-02-12 BUB1 promotes cell stem-like properties and serves as a diagnostic biomarker for lung cancer
2026-02-11 Efficacy and safety findings of the EXTRA study in older adult EGFR-mutant lung cancer patients receiving afatinib as first-line treatment
2026-02-08 STYK1 expression in breast cancer and its association with vascular invasion and clinicopathological features
2026-02-06 Therapeutic optimization of LIPA targeting to induce endoplasmic reticulum stress and cell death in ovarian cancer
2026-02-06 Afuresertib plus fulvestrant for pretreated HR-positive, HER2-negative, advanced breast cancer: a phase Ib trial
2026-01-29 Olutasidenib in recurrent/relapsed locally advanced or metastatic IDH1-mutated chondrosarcoma: phase 1b/2 trial
2026-01-28 Dalpicilib combined with cetuximab in patients with HPV-negative, anti-PD-1-resistant recurrent or metastatic head and neck squamous cell carcinoma: A phase II trial
2026-01-27 Treatment adherence and clinical outcomes of osimertinib in minority patients with advanced EGFR mutated NSCLC
2026-01-23 Racial differences in biomarkers, treatment, and outcomes in HR+/HER2- metastatic breast cancer in the United States
2026-01-20 The UFL1-AKT positive feedback loop promotes breast cancer progression by enhancing lipid synthesis
2026-01-19 Double-dose firmonertinib as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer harboring EGFR L858R mutation: a prospective, multicenter, phase II study (FIRM)
2026-01-19 KIN17 facilitates the initiation and progression of renal tumor progression through the PI3K-AKT-mTOR pathway
2026-01-17 Exploration of potential biomarkers in salivary duct carcinoma based on bioinformatics analysis
2026-01-17 QAL333’s antitumor activity and predictive modeling: integrated transcriptomic-bioinformatic analysis reveals selective cytotoxicity and sensitivity determinants
2026-01-16 Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trial
2026-01-16 Targeting PAK4 promotes Gemcitabine-induced pyroptosis in pancreatic cancer via NLRP1/caspase-3/GSDME axis
2026-01-13 MAT2A enhances PARN transcription via SRF to accelerate glycolysis and drive malignant progression in osteosarcoma